Current Research Studies
Cancer - ANHL1522: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Condition or Therapy:
Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Category:
Cancer and Blood Disorders
Study Number: ANHL1522
What is the goal of this study?
The main goal of this pilot study is to learn whether it is possible to provide the experimental treatment, LMP-specific T cells (LMP-TC), on time, to children and young adults with Positive Post-Transplant Lymphoproliferative Disease (PTLD) after a solid organ transplant.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are younger than 30 years old at the time of enrollment
- Have a history of solid organ transplantation
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106.
Study Location(s):
Seattle Children's Main Hospital Campus
Principal Investigator:
Dr. Rebecca Gardner
Research Center: Center for Clinical and Translational Research, Ben Towne Center for Childhood Cancer Research
